Tafamidis, a benzoxazole derivative that binds to T4-binding sites of TTR efficiently inhibiting the dissociation of tetramers, recently emerged as a very promising drug for the treatment of familial amyloid polyneuropathy [20] and TTR-mediated amyloid cardiomyopathy (ATTR-CM) [94]. Here, TTR is linked to cutaneous mastocytosis.